Quinoline-Proline, Triazole Hybrids: Design, Synthesis, Antituberculosis, Molecular Docking, and ADMET Studies

被引:4
作者
Ganesan, Moorthiamma Sarathy [1 ]
Raja, Kamatchi Kanmani [1 ]
Murugesan, Sankaranarayanan [2 ]
Karankumar, Banoth [2 ]
Faheem, Faheem [2 ]
Thirunavukkarasu, Sappanimuthu [3 ]
Shetye, Gauri [4 ]
Ma, Rui [4 ]
Franzblau, Scott G. [4 ]
Wan, Baojie [4 ]
Rajagopal, Gurusamy [5 ]
机构
[1] Govt Arts Coll Men, PG & Res Dept Chem, Chennai 600035, Tamil Nadu, India
[2] Birla Inst Technol & Sci, Dept Pharm, Med Chem Res Lab, Pilani Campus, Pilani, Rajasthan, India
[3] Orchid Pharma Ltd, Proc R&D, Chennai, Tamil Nadu, India
[4] Univ Illinois, Coll Pharm, Inst TB Res, Chicago, IL USA
[5] Chikkanna Govt Arts Coll, PG & Res Dept Chem, Tiruppur, India
关键词
D O I
10.1002/jhet.4229
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
A series of novel quinoline-proline hybrids (11a-g) and quinoline-proline-1,2,3-triazole hybrids (12-14) were synthesized by click chemistry based on molecular hybridization concept and were characterized by NMR, mass spectrometry, and elemental analysis. All the titled target compounds were tested for antitubercular activity by MABA and LORA methods by in vitro. Interestingly, two compounds (2R,4S)-1-((2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-methyl)-4-(4-nitrobenzamido)-N-phenylpyrrolidine-2-carboxamide (11b) and (2R,4S)-1-((2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-methyl)-4-(4-fluorobenzamido)-N-phenylpyrrolidine-2-carboxamide (11c) exhibited significant activity against the tested Mycobacterium tuberculosis H37Rv strain. Further, the cytotoxicity (CC50) profile of the titled compounds against the Vero cell was performed and discussed. A molecular docking study of the hit compounds (11b and 11c) was also performed to find their putative binding interaction with the active site of the target proteins. Finally, in silico ADMET properties were also predicted for all the synthesized molecules to evaluate their drug-likeness behavior.
引用
收藏
页码:952 / 968
页数:17
相关论文
共 35 条
  • [1] Alegaon S, 2020, FUTUR J PHARM SCI, V6, DOI 10.1186/s43094-020-0019-4
  • [2] [Anonymous], 2017, Global Tuberculosis Report
  • [3] Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy) acetamide-based antituberculosis agents
    Borsoi, Ana Flavia
    Paz, Josiane Delgado
    Abbadi, Bruno Lopes
    Macchi, Fernanda Souza
    Sperotto, Nathalia
    Pissinate, Kenia
    Rambo, Raoni S.
    Ramos, Alessandro Silva
    Machado, Diana
    Viveiros, Miguel
    Bizarro, Cristiano Valim
    Basso, Luiz Augusto
    Machado, Pablo
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 192
  • [4] The Modern Face of Synthetic Heterocyclic Chemistry
    Cabrele, Chiara
    Reiser, Oliver
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2016, 81 (21) : 10109 - 10125
  • [5] Casal J., 2017, Austin Tuberc Res Treat, V2, P1007
  • [6] Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis
    Cho, Sang Hyun
    Warit, Saradee
    Wan, Baojie
    Hwang, Chang Hwa
    Pauli, Guido F.
    Franzblau, Scott G.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) : 1380 - 1385
  • [7] Antifungal Styryloquinolines as Candida albicans Efflux Pump Inhibitors: Styryloquinolines are ABC Transporter Inhibitors
    Cieslik, Wioleta
    Szczepaniak, Joanna
    Krasowska, Anna
    Musiol, Robert
    [J]. MOLECULES, 2020, 25 (02):
  • [8] Darvas Ferenc, 2002, Current Topics in Medicinal Chemistry, V2, P1287, DOI 10.2174/1568026023392841
  • [9] Medicinal attributes of 1,2,3-triazoles: Current developments
    Dheer, Divya
    Singh, Virender
    Shankar, Ravi
    [J]. BIOORGANIC CHEMISTRY, 2017, 71 : 30 - 54
  • [10] The price of innovation: new estimates of drug development costs
    DiMasi, JA
    Hansen, RW
    Grabowski, HG
    [J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185